FAQ

The procedure is very simple. You rest your chin and forehead on the testing device, and a photo of your eye is taken. Unlike blood tests or CT scans, there's no needle involved or radiation exposure, making it completely safe and comfortable.

The effectiveness of using this product to predict cardiovascular disease has been validated by numerous case studies and publications in prominent journals such as The Lancet. It has also been officially approved by regulatory agencies like Korea's MFDS and Europe’s CE authorities.

No specific preparation is required. However, avoid activities that could affect autonomic nervous system balance or retinal blood flow just before the test—like smoking, caffeine, intense light exposure, or sudden temperature changes. It's recommended to wait at least one hour after taking hypertension medication and at least eight hours after alcohol consumption before testing.
* Evidence: https://doi.org/10.1111/aos.16938: Significant changes in vessel density observed after sympathetic/parasympathetic activation.
* Schuster et al., 2014: Meaningful correlation between HRV and retinal vessels.

It depends on the type of surgery. After uncomplicated cataract surgery, media opacity typically clears within a month, but waiting up to 3 months is recommended for higher accuracy. For laser-based surgeries, it's best to wait at least 4 months before testing.
* Evidence: https://doi.org/10.1186/s12886-020-01491-0: Up to 4 months recovery after LASIK.
https://doi.org/10.1371/journal.pone.0284181: Media opacity significantly reduced after 3 months post-surgery.

Dr. Noon CVD uses a predictive model, not a classification model, so its accuracy is evaluated using the C-index, not sensitivity or specificity. Its C-index is approximately 0.75, comparable to CT-based cardiovascular predictions (0.74) and more accurate than ultrasound-based predictions (0.71).
* C-index: Measures the predictive accuracy of a model. A value above 0.7 indicates acceptable predictive performance.
* Evidence: https://doi.org/10.1093/jamia/ocad199: Jamia pivotal study

Dr. Noon Fundus is an assistive software designed to detect and aid in the diagnosis of retinal diseases (such as diabetic retinopathy, macular degeneration, epiretinal membrane, retinal hemorrhage/occlusion, and other retinal disorders), glaucoma suspects, and cataract suspects.

In a clinical trial conducted at Seoul Asan Medical Center and Gangnam Severance Hospital, involving 182 patients with retinal conditions and 183 normal controls, the test demonstrated excellent diagnostic accuracy with the following AUC scores* for each condition:
● Retinal diseases: 0.93
● Glaucoma suspect: 0.95
● Cataract suspect: 0.96
In addition, agreement rates with ophthalmologists regarding the presence or absence of disease were as follows:
● Positive agreement: 92.39%
● Negative agreement: 95.48%
● Overall agreement: 93.91%

These results validate Dr. Noon Fundus as a high-performing diagnostic support software for ophthalmic conditions.
*AUC (Area Under the Curve): A performance metric for classification models, representing the area under the ROC curve. AUC values close to 1 indicate excellent classification performance. Generally, a value above 0.7 is considered good.
* Clinical Trial Reference: Multicenter, randomized, evaluator-blinded, retrospective, agreement validation confirmatory trial evaluating the efficacy of Dr. Noon for Fundus Screening (current product name - Dr. Noon Fundus) in detecting ocular abnormalities using retinal fundus images.

Unlike Heart CT or ultrasound assessments, Dr. Noon CVD poses no radiation risk and allows frequent imaging for monitoring. It also delivers accuracy that surpasses ultrasound-based methods.

It is validated for individuals aged 20–80, with no prior cardiovascular history, no heart surgery or intervention, and no eye surgery within the past 6 months. This test is predictive, not diagnostic, so it is not suited for acute cardiac symptoms (e.g., chest pain, shortness of breath), where emergency tests like ECG or echocardiogram are necessary.
* Evidence: https://doi.org/10.1093/jamia/ocad199

Yes. Even within the high-risk group (score 41+), a higher score indicates greater risk. Age distribution also matters—for example, a high-risk result in your 30s (seen in <5% of this group) signals a need for intensive management, while in the 70s age group, risk should be